Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23 and keeps a Buy rating on the shares. The firm, which is pulling its valuation forward, says it expects the next 12 months to be “an extremely catalyst-rich period” for Oric.